The Eye Doc Blog » announcement

Ribbon Cutting for The Total Eye Care Office in Colleyville

RAD — Tue, 24 Feb 2009 06:49:30 +0000

Thanks to all who attended our Ribbon Cutting Thursday and made it a smashing success. We would like to say thanks to the Colleyville Area Chamber of Commerce Ambassadors for christening our new building. We would also like to thank Ralph Zuranski for making the great video of our grand opening shown below. Check out Ralph’s website at www.InSearchOf heroes.com. Ralph is a photographer and videographer. We would also like to thank our business partners, CooperVision, Coach, Calvin Klein, Nautica, BCBGMaxazria, Bausch & Lomb and Hoya. Check out the video.

FDA Approves Latisse for the Treatment of Hypotrichosis of the Eyelashes

RAD — Sat, 27 Dec 2008 02:07:43 +0000

It’s official, as we reported a little over 2 weeks ago about pending approval of LATISSE(TM) to increase the length, number and darkness of a patient’s eyelashes Allergan made the announcement today that the FDA approved LATISSE(TM) (bimatoprost ophthalmic solution 0.03%), allowing it to be prescribed by doctors.

Available only through a doctor, LATISSE(TM) is a once-daily prescription treatment applied to the base of the upper eyelashes with a sterile, single-use-per-eye disposable applicator. LATISSE(TM) users can expect to experience longer, fuller and darker eyelashes in as little as eight weeks, with full results in 16 weeks. To maintain effect, continued treatment with LATISSE(TM) is required. If use of LATISSE(TM) is discontinued, eyelashes will gradually return to where they were prior to treatment over a period of weeks to months (average eyelash hair cycle).

LATISSE(TM) will be available in the United States by prescription only and is subject to all U.S. guidelines applicable to dispensing a prescription product. Based on today’s FDA approval, Allergan expects to launch the product nationwide in the first quarter of 2009.

In studies LATISSE(TM) was well tolerated with the most commonly reported adverse events being non-serious and cosmetic in nature. Common adverse events observed in the clinical trial included eye redness (3.6%), itchy eyes (3.6%) and skin hyperpigmentation (2.9%). LATISSE(TM) use may cause darkening of the eyelid skin which may be reversible. Although not reported in clinical studies, LATISSE(TM) use may also cause increased brown pigmentation of the colored part of the eye which is likely to be permanent.

Protect Your Eyes by Attending Professional Fireworks Displays This July 4th

RAD — Mon, 23 Jun 2008 12:05:35 +0000

Each year over the holiday, Thousands of adults and children are seriously injured as a result of fireworks and pyrotechnic devices. Many burns and injuries affect eyesight, permanently damaging and in some cases blinding the victims. The U.S. Consumer Product Safety Commission estimates that 20-25% of all fireworks related injuries involve the eyes.

Believe it or not, sparklers are the highest cause of fireworks injuries for children under five requiring trips to the emergency room. Another surprising fact is that 1/2 of the fireworks related injuries are to the bystanders. Be safe and attend a professional fireworks display in your area. More information and a list of fireworks displays in the Northeast Tarrant County is available.

Dr. Alycia Green Joins Total Eye Care

RAD — Wed, 23 Apr 2008 13:43:21 +0000

We are pleased to announce that Dr. Alycia Green has joined Total Eye Care! With the addition of Dr. Green we have expanded our hours at our Keller office. We will now offer appointments Monday through Friday at both the Colleyville and Keller offices. Saturday visits are available, by appointment, in Colleyville.

We are very excited to welcome Dr. Green to Total Eye Care. Dr. Green is a 1999 graduate of the University of Houston College of Optometry. A complete complete press release is available.